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The incidence of colorectal cancer (CRC) varies widely throughout 
the world.[1] Sub-Saharan countries, including South Africa, are 
reported to be areas with a low incidence of CRC compared with 
Western countries.[1-3] CRC in the Northern Cape province of 
South Africa is uncommon, a recent study reporting the age-
standardised rate to be 4.2/100 000[4] and the incidence to be one-
tenth that in the Western world.[3,5,6]
CRCs can be divided into two initial categories: those that 
occur sporadically and those with evidence of heritability. The 
latter category includes cases where the heritability is an obvious 
Mendelian pattern of dominant inheritance and those where 
the family merely has a higher than usual incidence of CRC. In 
economically developed countries, these three clinical patterns 
of occurrence account for approximately 70 - 85%, 10 - 20% and 
Background. In a previous study we identified 206 patients with colorectal adenocarcinoma in the Northern Cape province of South 
Africa, diagnosed between January 2002 and February 2009. The age-standardised incidence was 4.2/100 000 per year world standard 
population. This is 10% of the rate reported in First-World countries. In high-incidence areas, the rate of abnormal mismatch repair 
gene expression in colorectal cancers is 2 - 7%.
Objectives. The aim of this study was to determine the prevalence of hMLH1- and hMSH2-deficient colorectal cancer in the 
Northern Cape.
Methods. Formalin-fixed paraffin wax-embedded tissue blocks from 87 colorectal adenocarcinomas identified in the previous study 
were retrieved. Standard immunohistochemical staining methods were used to detect the expression of hMLH1 and hMSH2 (i.e. 
products of the hMLH1 and hMSH2 genes) in the tumours using heat-induced antigen retrieval and diaminobenzidene as a chromogen.
Results. In 8 blocks there was insufficient tumour tissue and in 1 case the immunohistochemical staining failed, probably owing to 
poor fixation, leaving 78 cases for analysis. In 11 cases hMLH1 was deficient and in 6 cases hMSH2 was deficient. Overall, 21.8% of 
cancers were deficient for hMLH1 or hMSH2.
Conclusion. Presuming that 80% of all hMLH1 deficiencies are due to hypermethylation of the gene, we found 10.5% of colorectal 
cancers in an area with a low incidence of colorectal cancer to be deficient in the product of the mismatch repair gene/s. This is 
approximately three times the reported rate in high-incidence areas.
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5 - 10%, respectively, of all cases of CRC.[7-12] Figures for developing 
countries are still unknown, but it is likely that their incidence of 
inherited CRC is similar to that of developed countries.
The most commonly inherited CRCs are familial adenomatous 
polyposis (FAP) and hereditary non-polyposis colon cancer (HNPCC) 
or Lynch syndrome (LS, as it is referred to when a disease-causing 
mutation is identified in the DNA mismatch repair genes). These 
syndromes are both the result of specific germline mutations. FAP 
accounts for less than 1% of CRCs. LS is the most common form of 
inherited CRC, accounting for 2 - 7% of all cases.[9,11,12]
There are a number of methods that can be used to make the 
clinical diagnosis of LS: analysis of family history using Amsterdam 
or Bethesda criteria;[13] tumour testing with immunohistochemistry 
(IHC) detecting the loss of DNA mismatch repair (MMR) gene 
product; tumour testing for microsatellite instability (MSI); or 
direct DNA genetic testing. Tumour IHC is a cheap and highly 
sensitive and specific strategy to screen for LS.[14-17]
An identified LS cohort in the Northern Cape has more 
than 100 individuals who undergo colonoscopy annually. The 
contribution of this group to the overall burden of CRC in a low-
incidence area is unknown. We hypothesise that in a low CRC 
incidence area, inherited cancers form a greater proportion of the 
overall disease burden. The aim of this study was to determine the 
prevalence of LS by testing for deficiency of hMLH1 and hMSH2 
(products of the hMLH1 and hMSH2 genes) with IHC in CRCs in 
the Northern Cape. This report is the first to attempt to provide 
prevalence data on inherited CRC in a low-incidence area.
Materials and methods
Ethics
Ethical approval was obtained from the Research Ethics 
Committee of the University of Cape Town, project reference no. 
129/2010.
Data collection and specimen retrieval
In a previous study, 206 patients with adenocarcinoma of the colon 
or rectum diagnosed between 2002 and 2009 in the Northern Cape 
were identified.[4] The formalin-fixed paraffin blocks of tumours of 
these patients were retrieved from the National Health Laboratory 
Service (NHLS) in Kimberley (Northern Cape) and Cape Town 
(Western Cape). At least 5 tissue sections of each specimen, with 
a thickness of 3 - 4 µm, were cut on a microtome (Accu-Cut SRM 
200 Rotary Microtome, Sakura Finetek, Torrance, CA, USA) and 
put on individual silane-coated slides (Marienfeld Laboratory 
Glassware, Lauda-Königshofen, Germany). All sections were heat-
fixed on the slides at 65˚C in an incubator (Lab Aire or Labaire 
Oven) for 30 minutes.
Histochemistry
On one section of each case, haematoxylin and eosin staining[18] 
was performed to make sure that all slides contained both normal 
colonic mucosa and tumour tissue on the same slide (Fig. 1, a). 
After dewaxing the sections in xylol for 3×3 minutes, sections were 
rehydrated through graded alcohols to water for 1 minute each. 
The series of alcohols consisted of three absolute alcohols, two 
96% alcohols and one 70% alcohol. Sections were counterstained 
in Mayer’s haematoxylin[18] for 9 minutes, destained in acid alcohol 
for 10 seconds, blued in Scott’s tap water substitute for 2 minutes, 
counterstained in eosin for 2 minutes, and dehydrated through 
graded alcohols to xylol. All slides were mounted in Entellan 
(Merck KGaA, Darmstadt, Germany).
Immunohistochemical analysis
Rationale
LS is an autosomal dominant inherited syndrome caused by 
germline mutations in one of the DNA-MMR genes, including 
hMSH2, hMLH1, hMSH6 and hPMS2. hMLH1 and hMSH2 are 
mutated in about 80 - 90% of all LS cases.[9,10,19] The deficiency 
of properly working MMR genes results in MSI. Microsatellites 
are repetitive DNA sequences of 1 - 4 base nucleotides that are 
particularly sensitive to DNA replication errors when the MMR 
system is absent.[20] Failure of the MMR system can ultimately 
lead to the occurrence of multiple colonic and extra-colonic 
tumours at an early age of onset. Tumour IHC testing for MMR 
proteins (hMLH1, hMSH2, hMSH6 and hPMS2) is an accurate 
marker for MMR gene product deficiency.[14,21] Absence of the 
product of one of these genes in a tumour would indicate that 
the tumour follows a MMR gene mutation pathway and might be 
inherited. Tumour IHC is a highly sensitive and specific strategy 
to screen for LS.[14-17]
Method
After dewaxing in xylol and rehydrating through graded alcohols 
to tap water, endogenous peroxidase activity was blocked using 
1% hydrogen peroxide (Cameron Chemical Consultants, Cape 
Town, South Africa) solution in methanol for 15 minutes. The 
slides were rinsed for 5 minutes in running tap water and antigenic 
sites were unmasked by heat-mediated antigen retrieval for 1.5 
minutes at full pressure in disodium ethylenediaminetetra-
acetate (EDTA) buffer, pH 8.0 (Protea Laboratory Services, 
Johannesburg, South Africa), by means of a Presto pressure cooker 
(Amalgamated Appliances Holdings, Reuven, South Africa). After 
cooling down in running tap water for 10 minutes, the slides were 
rinsed with phosphate-buffered saline-Tween (PBST) (Merck, 
München, Germany). Normal goat serum in phosphate buffer 
(Dako Denmark A/S), in a concentration of 1:20, was applied for 
10 minutes. The slides were drained and the respective mouse 
antibody was applied immediately at room temperature for 60 
minutes. The purified Mouse Anti-Human MLH-1, clone G168-15 
(Pharmingen, San Diego, CA, USA), was used at a final dilution of 
1/100 and Anti-MSH2 Mouse mAb, clone FE11 (Calbiochem), at 
a final dilution of 1/500. After rinsing with PBST, the secondary 
antibody Dako Envision+ System-HRP Labelled Polymer Anti 
mouse (Dako, Carpinteria, CA, USA) was applied for 30 minutes. 
Positivity was developed by applying the chromogenic substrate 
Dako Liquid DAB+ Substrate Chromogen System (Dako North 
America) for 8 minutes. Slides were rinsed with PBST and tap 
water and immersed in 1% copper sulphate for 10 minutes to 
enhance the DAB. Sections were lightly counterstained in Mayer’s 
haematoxylin[18] for 1 minute, blued in Scott’s tap water substitute 
for 2 minutes and dehydrated through graded alcohols to xylol. 
All slides were mounted in Entellan (Merck KGaA, Darmstadt, 
Germany).
Normal appendix and normal colonic mucosa were used as 
positive (intact expression) external controls for the assay. The 
negative (loss of expression) external control omitted the primary 
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antibody and substituted PBST. Internal control for each patient’s 
slide was the normal colonic mucosa adjacent to the tumour.
The immunohistochemical analysis was done according to CAP 
(College of American Pathologists) guidelines.[22]
Patient and tumour characteristics
In a previous study, pathology reports of all colorectal 
adenocarcinomas were retrieved from the NHLS in Kimberley and 
Cape Town. For this study, wherever possible, patient and tumour 
characteristics were obtained.[4]
Statistical analyses
Statistical analysis was performed using the STATA/IC 11 
program, and a chi-square test was utilised. For the characteristic 
synchronous lesion, where there were cell counts of <5, Fisher’s 
exact test was performed. A p-value of less than 0.05 was 
considered statistically significant.
Results
In this study of the original 206 cases, only 85 formalin-fixed 
paraffin blocks of tumours, together with the pathology reports, 
were retrieved from the NHLS in Kimberley and 2 blocks from 
their laboratories in Cape Town, resulting in a total of 87 cases. We 
excluded 119 cases because we were unable to retrieve the blocks 
or the pathology reports or could not obtain enough tumour tissue 
from the blocks.
In 8 of the 87 retrieved blocks, the sections did not 
contain sufficient tumour tissue. In 1 case the tumour was 
deficient for both hMLH1 and hMSH2, meaning that the 
immunohistochemical staining failed (i.e. the inbuilt control was 
negative); 78 blocks were therefore successfully analysed, of which 
45 were biopsies and 33 resection specimens (Fig. 2).
MMR gene product status
After immunohistochemical staining, 17 of the 78 tumours 
(21.8%) were deficient for hMLH1 or hMSH2; 11 were deficient 
for hMLH1 (Fig. 1, b) and in 6 cases hMSH2 product was absent. 
Intact expression of hMSH2 is shown in Fig. 1, c. Clinical and 
pathological features of specimens deficient for hMLH1 or hMSH2 
are summarised in Table 1.
Age/gender
Ages were not available for 2 of the 78 patients. The median 
age at diagnosis of adenocarcinoma was 58.5 years (standard 
deviation (SD) 15 years). There was no significant difference in 
mean age between the two groups (56.9 years in gene product-
deficient tumours v. 58.9 years in tumours in which gene product 
was present). Of the 76 tumours, 20 (26.3%) were diagnosed in 
patients under the age of 50 years, of which 7 (9.2% of the total) 
were deficient for gene product on immunohistochemical staining. 
However, this was not statistically significant (p=0.114). Of the 
patients, 34 (42.6%) were men and 44 (56.4%) women. There was 
no difference in gene product status by gender.
Histological features
The majority of the CRCs were regular adenocarcinomas, but in 
8 cases (10.3%) the tumour was a mucinous or signet ring cell 
carcinoma. There was a significant difference (p=0.041) in MMR 
status by histological type, with more mucinous and signet ring cell 
carcinomas among the MMR-deficient tumours (23.5% v. 6.6%).
Differentiation
The grade of differentiation was identified in 67 cases: 59 
tumours (88.1%) were moderately or well differentiated and 8 
(11.9%) were poorly differentiated. The MMR-deficient tumours 
Fig. 1. Immunohistochemical staining. (a) Haematoxylin and eosin staining, 
containing both normal colonic mucosa and tumour tissue. (b) Staining for 
hMLH1: intact expression in internal control and loss of expression in tumour 
tissue. (c) Staining for hMSH2: intact expression in both internal control and 
tumour tissue.
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were more often poorly differentiated 
(p=0.002).
Site
The site of the CRC could be identified 
from the pathology report in 71 cases: 
11 tumours (14.1%) were right sided, 
and 60 (76.9%) left sided. There was a 
significant difference in lesion location 
(p=0.001), with the MMR-deficient group 
representing more right-sided tumours.
T classification
In half of the tumours T stage could be 
identified. A T stage of more than T2 
was identified in 91.7% of tumours with 
gene product deficiency and in 57.1% of 
tumours with gene product. There was 
a significant difference (p=0.019) in 
MMR status by T stage (>T2 and ≤T2), 
with a higher T stage in the gene product-
deficient tumours. 
Number of tumours
In 3 cases there were multiple lesions; 2 
with one other lesion and 1 with two other 
lesions. In all 3 cases hMLH1 and hMSH2 
were present.
Discussion
We chose IHC for this study because this 
method is an accurate marker for MMR 
gene product deficiency, is available 
in most pathology laboratories and is 
relatively cheap.[14] Mutations in hMLH1 
and hMSH2 occur in 80 - 90% of all LS 
cases. We chose to detect mutations in 
these two genes to identify patients with 
inherited CRC (specifically LS).
Although all LS cancers are associated 
with mutations in the MMR genes, 
sporadic cancers can also follow an MMR 
(gene mutation) pathway. It is estimated 
that up to 15% of sporadic cancers will 
follow this pathway.[15,16,23-25] In around 80% 
of these MSI-high tumours with hMLH1 
deficiency, DNA MMR genes are inactivated 
due to promoter hypermethylation of the 
hMLH1 gene.[25-27] Neither MSI nor IHC can 
differentiate between cancers caused by LS 
and sporadic cancers that follow the MMR 
pathway.
We found 21.8% of all CRCs in the 
Northern Cape to be deficient for hMLH1 
or hMSH2. In 14.1% of tissue analysed, 
tumours were deficient for hMLH1, and 
in 7.7% hMSH2 was absent. One would 
expect that around 80% of the 11 hMLH1-
deficient tumours would show protein 
loss due to hypermethylation of hMLH1 
promoter (i.e. sporadic mutation), and 
one could therefore estimate that 10.5% 
of all CRCs in the Northern Cape would 
be expected to be MMR gene product-
deficient due to germline mutations.
This estimated frequency of hMLH1 and 
hMSH2 deficiency is approximately two 
to four times the reported rate in high-
incidence areas.[9,11,12] These results support 
our hypothesis that in a low-incidence area 
the inherited form contributes a greater 
proportion of the overall CRC burden as 
a result of a reduction in the incidence of 
sporadic CRC.
LS is characterised by several properties 
such as colonic and extra-colonic 
tumours at an early age of onset (<50 
years); synchronous and metachronous 
CRC; mucinous and signet ring tumours; 
predominance of right-sided CRC; and 
poor differentiation.[10] In this study we 
used these characteristics, apart from 
the presence of hMLH1 and hMSH2, 
to identify MMR-deficient tumours. 
Unfortunately inadequate family history 
did not allow us to use the Bethesda or 
Amsterdam guidelines.
In the group of tumours with MMR 
deficiency, more patients were younger 
(<50 years) at time of diagnosis (41.2% 
v. 22.0%) although analysis did not show 
a statistically significant difference. A 
mean age of 56.9 years (SD 14 years) was 
determined (range 31 - 76 years) in the 
gene product-deficient tumours. This 
mean age was lower than the 58.9 years 
(SD 16 years) in the group with presence 
of gene product, but the difference was 
not significant. Hampel et al.[27] reported 
a mean age of 50.4 years. Mucinous and 
signet ring cells were more often identified 
(p=0.041) in the gene product-deficient 
group (23.5% v. 6.6%), and more tumours 
were poorly differentiated (35.7% v. 5.7%) 
(p=0.002). T stage was higher (p=0.019) 
in this group as well, and tumours were 
more often right-sided (35.3% v. 6.6%) 
(p=0.001). These results support our 
hypothesis that CRC tumours deficient for 
hMLH1 and hMSH2 are inherited.
Identifying LS families, and detecting 
the individuals who are mutation-
positive, is necessary, as colonoscopic 
screening of those found to carry the 
predisposing mutation can enable early 
detection of CRC and reduce mortality 
by 65%.[28-29] These patients have a lifetime 
risk of developing colorectal and extra-
colonic cancer associated with LS of over 
90%,[30] and lifelong surveillance for these 
cancers is indicated.[9,10] The possible high 
frequency of inherited CRC in this study 
shows the importance of identification of 
potential carriers of germline mutations in 
all low-incidence areas.
A few comments should be made 
concerning our research. In this study 
we chose to test for the products of the 
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Fig. 2. Data collection and specimen retrieval.
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hMLH1 and hMSH2 genes only. These two genes account for 
almost 80 - 90% of all identified mutations in LS, meaning that this 
method does not identify mutations in all MMR genes responsible 
for LS and underestimates the total number of LS cases.[10]
It should also be noted that the group of hMLH1-deficient 
tumours in this study may include some sporadic tumours. As 
mentioned above, a number of MSI-high tumours that do not 
stain for the hMLH1 product have inactivated MMR genes due 
to hMLH1 promoter hypermethylation. This is why absence of 
hMLH1 with IHC on its own is not specific for LS.
A proportion of all tumours in this study showing hMLH1 
deficiency are expected to be sporadic. The presence of hMLH1 
hypermethylation does not exclude the possibility of a germline 
mutation,[25,31] but determination of BRAF mutations can be used to 
detect LS, as the presence of a BRAF mutation argues against LS.[15,32]
In conclusion, our study provides data suggesting that the 
frequency of MMR deficiency in CRC is relatively high in an 
area with a low incidence of CRC compared with high-incidence 
areas in the Western world. These results mean that if a CRC 
surveillance programme is to be effective, it is important to 
identify LS patients in a low-incidence area.[29]
The proportion of MMR-deficient CRCs of 10.5% in this study 
is based on a calculation, and a future study needs to be done to 
confirm that these tumours with MMR deficiency have germline 
mutations. Testing for a BRAF mutation is necessary to eliminate 
the sporadic tumours in all hMLH1-deficient cases. On all 
tumours showing hMLH1 and hMSH2, gene product IHC testing 
for MMR proteins hMSH6 and hPMS2 needs to be performed to 
identify missed MMR gene-deficient tumours.
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Table 1. Clinical and pathological features of specimens deficient for hMLH1 or hMSH2
Characteristics
Gene product deficient
n/N (%)
Gene product present
n/N (%)
Total
n/N (%) p-value
Gender 0.379
Male 9/17 (52.9) 25/61 (41.0) 34/78 (43.6)
Female 8/17 (47.1) 36/61 (59.0) 44/78 (56.4)
Age at diagnosis (years) 0.114
<50 7/17 (41.2) 13/59 (22.0) 20/76 (26.3)
≥50 10/17 (58.8) 46/59 (78.0) 56/76 (73.7)
Unknown 0 2 2  
Histological type 0.041
Adenocarcinoma 13/17 (76.5) 57/61 (93.4) 70/78 (89.7)
Mucinous or signet ring cell 4/17 (23.5) 4/61 (6.6) 8/78 (10.3)
Grade of differentiation 0.002
Moderate or well 9/14 (64.3) 50/53 (94.3) 59/67 (88.1)
Poor 5/14 (35.7) 3/53 (5.7) 8/67 (11.9)  
Unknown 3 8 11  
Side 0.001
Left-sided 7/13 (53.8) 53/58 (91.4) 60/71  (84.5)
Right-sided 6/13 (46.2) 5/58 (8.6) 11/71 (15.5)
Unspecified 4 3 7
T classification 0.019
T1 or T2 1/12 (8.3) 12/28 (42.0) 13/40 (23.5)
>T2 11/12 (91.7) 16/28 (57.1) 27/40 (67.5)  
Unknown 5 33 38  
Synchronous/metachronous tumour 0.527*
Yes 1/17 (5.9) 2/61 (3.3) 3/78 (3.8)
No 16/17 (94.1) 59/61 (96.7) 75/78 (96.2)
Type of specimen 0.008
Biopsy 5/17 (29.4) 40/61 (65.6) 45/78 (57.7)
Resection 12/17 (70.6) 21/61 (34.4) 33/78 (42.3)  
*Fisher’s exact test.
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